Page last updated: 2024-08-24

ranolazine and Dyslipidemia

ranolazine has been researched along with Dyslipidemia in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	3 (100.00)	2.80

Authors

Authors	Studies
Braczko, A; Chlopicki, S; Jablonska, P; Jedrzejewska, A; Krol, O; Kus, F; Mika, A; Przyborowski, K; Sledzinski, T; Slominska, EM; Smolenski, RT; Tomczyk, M	1
Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Schmidt, CW; Storey, KM; Traverse, JH; Wang, J	1
Janardanan Subramonia, K; Karunanidhi Santhana, L; Ravula, SR; Thangavel Mahalingam, V	1

Trials

1 trial(s) available for ranolazine and Dyslipidemia

Article	Year
Effect of ranolazine as add-on therapy in type 2 diabetic dyslipidaemia patients: A randomised open-label trial. International journal of clinical practice, 2021, Volume: 75, Issue:4 Topics: Acetanilides; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Ranolazine	2021

Other Studies

2 other study(ies) available for ranolazine and Dyslipidemia

Article	Year
Enhanced Muscle Strength in Dyslipidemic Mice and Its Relation to Increased Capacity for Fatty Acid Oxidation. International journal of molecular sciences, 2021, Nov-12, Volume: 22, Issue:22 Topics: Adenine Nucleotides; Animals; Apolipoproteins E; Blood Glucose; Dyslipidemias; Fatty Acids; Insulin Resistance; Lipids; Mice, Inbred C57BL; Mice, Knockout; Mitochondria, Muscle; Muscle Strength; Muscle, Skeletal; Myosin Heavy Chains; Oxidation-Reduction; Ranolazine; Receptors, LDL; Troponin	2021
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry). The American journal of cardiology, 2020, 08-15, Volume: 129 Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome	2020

Article

Year

Enhanced Muscle Strength in Dyslipidemic Mice and Its Relation to Increased Capacity for Fatty Acid Oxidation.

International journal of molecular sciences, 2021, Nov-12, Volume: 22, Issue:22

Topics: Adenine Nucleotides; Animals; Apolipoproteins E; Blood Glucose; Dyslipidemias; Fatty Acids; Insulin Resistance; Lipids; Mice, Inbred C57BL; Mice, Knockout; Mitochondria, Muscle; Muscle Strength; Muscle, Skeletal; Myosin Heavy Chains; Oxidation-Reduction; Ranolazine; Receptors, LDL; Troponin

2021

Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).

The American journal of cardiology, 2020, 08-15, Volume: 129

Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome

2020